Navigation Links
New Eloxatin(R) (oxaliplatin injection) Prescribing Information in the U.S. Includes Six-Year Overall Survival Data
Date:5/27/2008

de 1, and 12% were severe (grades 3 and 4). Partial or total recovery was observed within 18 months following treatment in most patients experiencing grade 3 peripheral sensory neuropathy. Patients treated with FOLFOX4 also reported nausea (73.7%), diarrhea (56.3%) and vomiting (47.2%).

"This announcement is welcome news for patients who have a significantly higher chance of surviving Stage III colon cancer when treated with the Eloxatin-based regimen following surgery," noted Dr. de Gramont. "Inclusion of these survival results in the new U.S. Eloxatin PI marks an important milestone in the treatment of colon cancer."

About MOSAIC

Eloxatin(R) in combination with infusional 5-FU/LV was first granted U.S. approval in 2004 for the treatment of Stage III colon cancer patients who have their primary tumors surgically removed based on the disease-free survival data from MOSAIC after a median follow-up of three years. At the time of the original analysis, there was no demonstrated benefit in overall survival after a median follow-up of four years.

Supported by sanofi-aventis, the phase III controlled MOSAIC trial was conducted in 148 centers in 20 countries. In MOSAIC, 2,246 patients with Stage II or Stage III colon cancer whose tumor had been completely surgically removed were randomized to treatment with either the Eloxatin-based FOLFOX4 regimen (n=1,123) or standard chemotherapy 5-FU/LV (n=1,123) every two weeks for 12 cycles. The primary endpoint evaluated how the addition of Eloxatin affected disease-free survival at three years. Secondary endpoints included overall survival and safety, including long-term adverse effects.

About Colorectal Cancer

Stage II colorectal cancer indicates that the cancer has grown through the wall of the colon or rectum but has not yet spread to nearby lymph nodes. At Stage III, the cancer has invaded one or more of the local lymph nodes but has not spread to distant sites. Metastatic colorectal ca
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
2. Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases
3. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
4. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
5. ORTHO EVRA(R) Prescribing Information Updated
6. ImpactRx Tracks Decline in Zetia and Vytorin Prescribing
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
8. Researcher Investigates Disparities in Doctor-Patient Information Exchange During Clinical Trial Offers
9. Initiation of Coverage Informational Review Issued by Scimitar Equity Research
10. Berkery Noyes Represented The Thomson Corporation in the Sale of CenterWatch and New England Institutional Review Board to Jobson Medical Information
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... and NEW YORK , Sept. ... SAS and the Hereditary Neuropathy Foundation (HNF) announced today ... awareness around Charcot-Marie-Tooth (CMT) disease and support the development ... Pharnext will provide financial support to several ... development of a specific section in the HNF website ...
(Date:9/15/2014)... 2014 /PRNewswire/ -  Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ... with a focus on Omega-3 therapies for cardiovascular ... Board of Directors approved the granting of stock ... close of business on Friday, September 12, 2014. ... shares of the Company were granted in accordance ...
(Date:9/15/2014)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... Valeant Pharmaceuticals International, will redeem all of the outstanding ... Notes due 2017, CUSIP Nos. 91911XAL8, U9098VAD4 (the " ... an irrevocable notice of redemption for the Notes. ... irrevocable notice of redemption with respect to the remaining ...
Breaking Medicine Technology:Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 2Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 3Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 4Pivotal Therapeutics Grants Incentive Stock Options 2Valeant Announces Redemption of All of the Outstanding $500.0 Million Aggregate Principal Amount of its 6.75% Senior Notes due 2017 2
... , , JERUSALEM, Israel, January 11 ... systems, today announced that it has filed two registration,statements on ... One registration statement relates to a proposed ... and warrants to purchase 12,million shares of common stock, as ...
... , SAN JOSE, Calif., Jan. 11 Finesse Solutions, ... life sciences process applications, announced the production release of ... oxygen or pH and process temperature, and TruTorr headspace ... accuracy, lifetime, and ease of use. It is available ...
Cached Medicine Technology:Oramed Pharmaceuticals Announces Filing of Two Registration Statements 2Oramed Pharmaceuticals Announces Filing of Two Registration Statements 3Single-Use Sensor Product Family Enters High Volume Production 2
(Date:9/16/2014)... (PRWEB) September 16, 2014 Synergy Research ... comprehensive report gives the best detail and analysis of ... pulled from a variety of sources, including Ministry of ... Orange Paper will give readers actionable intelligence on clinical ... Paper is relied on by the local and international ...
(Date:9/16/2014)... Florida Hospital announced today it is teaming up ... and become the Presenting Sponsor of the 2014-15 and ... and wellness partner. As the Presenting Sponsor for the ... and name inclusion on all Lightning advertising campaigns and ... been a sponsorship partner of the Lightning since 2011, ...
(Date:9/16/2014)... Whatisfinalexpenseinsurance.com has released a new ... life insurance for seniors. , Finding affordable life insurance ... big part of the insurance market has moved online. ... that clients can use when shopping for life coverage. ... important for providing financial security for vulnerable family members. ...
(Date:9/16/2014)... serve of dairy food may reduce the risk of ... foods have not traditionally formed part of the diet. ... by Emeritus Professor Mark Wahlqvist from Monash University,s Department ... Institute, considered the role increased consumption of dairy foods ... longevity. , "In a dominantly Chinese food culture, ...
(Date:9/16/2014)... 15, 2014A comparison of five-year sexual function ... external beam radiotherapy (EBRT) versus combination EBRT ... vessel-sparing radiation therapy makes cure possible without ... presented today at the American Society for ... , The study examined the patient-reported outcomes ...
Breaking Medicine News(10 mins):Health News:Synergy Research Group Debuts Ukraine Orange Paper 2Health News:Florida Hospital Teams up with the Tampa Bay Lightning as the New Presenting Sponsor of the 2014-15 and 2015-16 Lightning Seasons 2Health News:Florida Hospital Teams up with the Tampa Bay Lightning as the New Presenting Sponsor of the 2014-15 and 2015-16 Lightning Seasons 3Health News:Life Insurance for Seniors - Clients Can Find Fast Life Insurance By Comparing Online Quotes! 2Health News:A heart-felt need for dairy food 2Health News:Prostate cancer patients surveyed 5 years after vessel-sparing RT report preserved sexual function 2Health News:Prostate cancer patients surveyed 5 years after vessel-sparing RT report preserved sexual function 3
... and longevity to health status and quality of life. Researchers ... longer, but the quality of life in later years must// ... benefits of staying physically active in your later years. The ... to perform their daily activities easier later in life. ...
... for a cure for diabetes. A new study done in ... insulin producing //pancreatic islet cells. This could lead to a ... research is a follow up to the 2001 report of ... The new research focuses on the biological mechanism behind that ...
... a deterioration of the retina, is the number one cause ... significantly // reduce the number of people with vision loss ... ,A couple of years ago, researchers conducted a ... vitamins C, E, and beta carotene, along with zinc oxide ...
... lifestyle changes and medication can prevent or delay the onset ... used to identify high-risk individuals for diabetes, but the test ... of risk //factors known as metabolic syndrome is able to ... ,Metabolic syndrome has been shown to lead to the ...
... eat play a role in whether you’ll end up with ... women between //ages 20 and 40 for one year. Their ... at least eight servings of fruits or vegetables a day ... than those who ate their usual diets. ,The ...
... a historic vote Friday night on a bill that would ... // of the politically popular entitlement program in its 38-year ... have lined up in our favor," House Speaker Dennis Hastert ... time is upon us. It's now or never." ...
Cached Medicine News:Health News:Predictors for Type 2 Diabetes 2Health News:House heads for Medicare drug vote, 2Health News:House heads for Medicare drug vote, 3
... onsite test! QuickScreen multi-panel dip cards offer ... your choice of any conceivable combination of ... flexibility for your drug testing program. Just ... the built-in timer tells you when to ...
... Screen Tests are available in 14 configurations ... Designed using Microgenics Antibody Technology, the SureStep™ ... of care immunoassay targeted to detect MDMA ... and MDEA but no cross-reactivity to any ...
Accu-Stat Home Drug Test for Marijuana (THC), Cocaine (COC), Amphetamine (AMP), Methamphetamine (mAMP), Opiates (OPI), and Phencyclidine (PCP)....
... are highly accurate in detecting the presence of ... by GC/MS testing. This assay provides a preliminary ... as GC/MS) must be used in order to ... applied to any drug of abuse test result, ...
Medicine Products: